This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Shipping:
Cold Chain Shipping
Imjudo (tremelimumab) is shipped under strict cold chain conditions to preserve its stability and effectiveness. Specialized medical couriers use temperature-controlled packaging and vehicles to maintain appropriate storage conditions throughout transit. This ensures that the medicine remains uncompromised and safe for patient use.
Disease Indication:
• Unresectable Hepatocellular Carcinoma (uHCC) / Liver Cancer
Manufacturer:
AstraZeneca Pharmaceuticals LP
Usage:
Intravenous
Imjudo (tremelimumab)
General Description:
Imjudo (tremelimumab) is a monoclonal antibody that targets and blocks CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4), an immune checkpoint protein that can suppress the body’s immune response against cancer cells. It is indicated only in combination with Imfinzi (durvalumab) for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC), the most common form of liver cancer.
By blocking CTLA-4, Imjudo helps enhance the immune system’s ability to recognize and attack cancer cells. When used with Imfinzi, it provides a synergistic effect that improves overall treatment outcomes for patients with advanced liver cancer.
Imjudo is administered intravenously under the supervision of a qualified oncologist in a clinical setting. The treatment plan and dosage are determined based on individual patient needs and medical evaluation.
Getting Imjudo (tremelimumab) in India
Imjudo, in combination with Imfinzi, has been approved by major international health authorities, including the U.S. Food and Drug Administration (FDA) in October 2022, for the treatment of unresectable hepatocellular carcinoma. It is also approved by the European Medicines Agency (EMA) and Pharmaceuticals and Medical Devices Agency (PMDA).
Although not yet widely available in India, eligible patients can access Imjudo through a Named Patient Program (NPP) under the guidance of a licensed physician.
MitoGENE supports Indian patients in obtaining Imjudo (tremelimumab) safely and compliantly. Our team coordinates all regulatory documentation, import permits, and logistics to ensure a transparent, secure, and patient-centered process.
Medicine Approved By:
• Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Pharmaceuticals and Medical Devices Agency (PMDA)
Available Dosage Form & Package:
• 25 mg/1.25 mL (20 mg/mL) solution in a single-dose vial
• 300 mg/15 mL (20 mg/mL) solution in a single-dose vial
How to Access Imjudo (tremelimumab in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Imjudo (tremelimumab) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
